Validation of New Diagnostic Indices to Simplify Hyponatremia Therapy Assessment in Patients on Thiazide Diuretics
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Apr 19, 2024
Trial Information
Current as of November 13, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is examining two new methods, called aSID and ChU, to help doctors better understand and treat low sodium levels (known as hyponatremia) in patients taking a type of medication for high blood pressure called thiazide diuretics. The goal is to see if these new methods can help doctors identify the cause of low sodium levels and decide on the best treatment, potentially improving patient care compared to current methods.
To participate in the study, you must be at least 18 years old, hospitalized at University Hospital Basel, and have a low sodium level along with certain other health indicators. However, if you have severe health issues requiring immediate treatment, such as significant heart or liver problems, or if you are pregnant or breastfeeding, you won’t be eligible. Participants in the trial can expect close monitoring and care from the research team as they explore these new diagnostic methods. This study aims to make it easier for doctors to manage low sodium levels in patients on thiazide medications, ultimately leading to better treatment outcomes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Hospitalized patients presenting at University Hospital Basel
- • aged 18 years or older
- • able to give informed consent as documented by signature
- • with serum sodium level \< 130 mmol/l and serum osmolality \< 300 mOsm/kg
- • with treatment with thiazide or thiazide-like diuretic
- Exclusion Criteria:
- • symptomatic hyponatremia in need of 3% hypertonic solution or intensive care treatment
- • inability or contraindications to undergo the trial (i.e., any acute severe cardiovascular event requiring an immediate intervention)
- • decompensated liver cirrhosis CHILD C
- • decompensated heart failure NYHA III or higher
- • severe valve impairment
- • untreated adrenal insufficiency
- • severe kidney disease in need of dialysis
- • pregnancy or breastfeeding
- • end of life care
- • inability to follow the study procedures (i.e., language problem, dementia or critical illness).
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, Switzerland
Patients applied
Trial Officials
Laura Potasso, Dr. med. sc.
Principal Investigator
University Hospital, Basel, Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported